A Study Investigating a Single Dose of 13-Valent Pneumococcal Conjugate Vaccine in Japanese Participants Aged 6 to 64 Years With Illnesses That Mean They Are More Likely to Get Pneumococcal Disease

Final Report: A Phase 3, Multicenter, Single-Arm, Open-Label Study to Assess the Safety, Tolerability, and Immunogenicity of a Single Dose of 13-Valent Pneumococcal Conjugate Vaccine in Japanese Subjects Aged 6 to 64 Years Who are Considered to be at Increased Risk of Pneumococcal Disease and Who are Naive to Pneumococcal Vaccines

Category & Conditions:
Vaccine-related Conditions
Medicine:
PREVNAR 13(PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE [DIPHTHERIA CRM197 PROTEIN])
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
B1851172
Open Plain Language Summary Result:Click here